UBS Group AG Sells 203,929 Shares of Charles River Laboratories International, Inc. $CRL

UBS Group AG lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 34.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 388,827 shares of the medical research company's stock after selling 203,929 shares during the quarter. UBS Group AG owned approximately 0.79% of Charles River Laboratories International worth $77,563,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRL. Vanguard Group Inc. raised its holdings in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company's stock valued at $1,174,374,000 after acquiring an additional 47,432 shares in the last quarter. Invesco Ltd. increased its position in Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company's stock valued at $195,446,000 after purchasing an additional 12,035 shares during the period. Bank of America Corp DE increased its position in Charles River Laboratories International by 13.4% during the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company's stock valued at $182,017,000 after purchasing an additional 137,335 shares during the period. Dimensional Fund Advisors LP raised its holdings in Charles River Laboratories International by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company's stock worth $176,909,000 after purchasing an additional 120,207 shares in the last quarter. Finally, Earnest Partners LLC lifted its position in shares of Charles River Laboratories International by 0.8% in the 3rd quarter. Earnest Partners LLC now owns 1,006,724 shares of the medical research company's stock worth $157,512,000 after purchasing an additional 8,467 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $165.92 on Monday. The business has a fifty day moving average price of $169.78 and a 200-day moving average price of $183.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The company has a market capitalization of $8.19 billion, a PE ratio of -56.05, a PEG ratio of 2.01 and a beta of 1.44. Charles River Laboratories International, Inc. has a 1-year low of $113.89 and a 1-year high of $228.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the prior year, the firm posted $2.66 earnings per share. The business's revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CRL shares. Barclays lifted their target price on shares of Charles River Laboratories International from $200.00 to $210.00 and gave the company an "overweight" rating in a research note on Tuesday, April 14th. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a research report on Thursday, February 19th. Evercore reiterated an "outperform" rating on shares of Charles River Laboratories International in a report on Wednesday, April 8th. Citigroup raised their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the company a "buy" rating in a research note on Friday, January 16th. Finally, JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $165.00 to $160.00 and set a "neutral" rating on the stock in a research report on Monday, April 13th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of "Moderate Buy" and a consensus price target of $205.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.